HomeMost PopularInvestingGilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

Actionable Trade Ideas

always free

Gilead Sciences Inc. GILD is set to report first-quarter 2024 results on Apr 25, after market close. In the last reported quarter, the company posted an earnings surprise of -2.27%.

Gilead Sciences, Inc. Price, Consensus and EPS Surprise

Gilead Sciences, Inc. Price, Consensus and EPS Surprise

Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote

Factors to Note

Gilead has a market-leading HIV franchise, led by flagship HIV therapies β€” Biktarvy and Descovy. However, revenues in the first quarter might have been impacted by a decline in HIV franchise sales. The first quarter is typically impacted by the reset of patient copays and deductibles. In addition, inventory build-up in the fourth quarter leads to notable draw-downs by wholesalers in the first quarter, thereby impacting revenues. Gilead expects a 10-12% decline in HIV sales in the first quarter of 2024.

While market share gains and continued double-digit growth in demand for HIV prevention for Biktarvy drove sales in 2023, Biktarvy missed the consensus mark in the fourth quarter of 2023. The trend is likely to have continued in the first quarter. Descovy’s revenues, too, missed the consensus estimate in the previous quarter.Β  The top line is expected to have declined in the first quarter.

The first-quarter top-line estimate for Biktarvy and Descovy is pegged at $2.9 billion and $476 million, respectively, and our model estimate for the same is pinned at $2.8 billion and $460 million.

The Liver Disease portfolio sales include chronic hepatitis C virus, chronic hepatitis B virus and chronic hepatitis delta virus. Higher demand for chronic hepatitis delta virus products and chronic hepatitis B virus has likely boosted sales of this franchise in the first quarter.Β 

Veklury sales continue to be highly variable. Higher COVID-related hospitalizations in the fourth quarter enabled Veklury to beat on sales. However, the trend has likely not continued in the first quarter of 2024.

Cell Therapy product sales have likely seen a slight increase in the first quarter. Yescarta sales are primarily being driven by increased demand in the second and third-line settings for relapsed or refractory (R/R) large B-cell lymphoma outside the United States.

Tecartus (brexucabtagene autoleucel) sales are being driven by increased demand in adult R/R B-cell precursor acute lymphoblastic leukemia and mantle cell lymphoma. However, sales growth in the United States continues to be slower than anticipated, while that in Europe continues to be strong.

Both the Zacks Consensus Estimate and our estimate for Cell Therapy product sales in the first quarter are pinned at $473 million.

Increased sales of Trodelvy, indicating continued solid uptake in metastatic triple-negative breast cancer, have also likely boosted sales in the first quarter. Approval of the drug in Europe is also expected to have a positive impact on sales. The Zacks Consensus Estimate and our estimate for Trodelvy sales are pinned at $323 million and $314 million, respectively.

Operating expenses are likely to have remained flat sequentially in the first quarter due to a decline in the growth of R&D and SG&A expenses.

Pipeline & Regulatory Update

Apart from the regular top and bottom-line numbers, we expect investors to focus on key pipeline updates when the company reports first-quarter results.

Gilead recently acquired a clinical-stage biopharmaceutical company, CymaBay Therapeutics, Inc., for $4.3 billion. The acquisition added CymaBay’s investigational lead product candidate, seladelpar, to Gilead’s pipeline. Seladelpar is an investigational, oral, selective peroxisome proliferator-activated receptor delta agonist, shown to regulate critical metabolic and liver disease pathways. A new drug application seeking approval of the candidate for the treatment of primary biliary cholangitis (PBC) was submitted to the FDA in December 2023. The FDA granted priority review to the same with a target action date of Aug 14, 2024.

Earnings Surprise History

GILD’s earnings missed estimates in three of the trailing four quarters and beat the same in one, delivering an average negative surprise of 3.64%.

Share Price Performance

Gilead’s shares have lost 17.6% year to date compared with the industryβ€˜s decline of 11%.

Zacks Investment Research
Image Source: Zacks Investment Research

What Our Model Predicts

Our proven model does not conclusively predict an earnings beat for Gilead this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below.

Earnings ESP:Β  Earnings ESP for GILD is -89.07% as the Zacks Consensus Estimate is currently pinned at $1.03 per share and the Most Accurate Estimate is presently pegged at 11 cents per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #3.

Stocks to Consider

Here are some drug and biotech stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this reporting cycle.

Oncolytics Biotech ONCY has an Earnings ESP of +5.88% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

ONCY beat on earnings in three of the trailing four quarters and missed the same in one, delivering an average surprise of 5.20%.

Omega Therapeutics OMGA has an Earnings ESP of +7.25% and a Zacks Rank #2 at present.

OMGA beat on earnings in three of the trailing four quarters and missed the same in one, delivering an average surprise of 16.04%.

Fate Therapeutics FATE has an Earnings ESP of +2.53% and a Zacks Rank #3 at present.

FATE beat on earnings in each of the trailing four quarters, delivering an average surprise of 28.86%. Shares of FATE have risen 28.1% in the past year.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Β 

Where Will Stocks Go…

If Biden Wins? If Trump Wins?

The answers may surprise you.

Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!

Now is the time to download Zacks’ free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…

1. Medical manufacturer has gained +11,000% in the last 15 years.

2. Rental company is absolutely crushing its sector.

3. Energy powerhouse plans to grow its already large dividend by 25%.

4. Aerospace and defense standout just landed a potentially $80 billion contract.

5. Giant Chipmaker is building huge plants in the U.S.Β 

Hurry, Download Special Report FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

Oncolytics Biotech Inc. (ONCY) : Free Stock Analysis Report

Fate Therapeutics, Inc. (FATE) : Free Stock Analysis Report

Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.